Navigation Links
Biocept, Inc. Announces New Director Appointment - September 28, 2010

SAN DIEGO, Oct. 7 /PRNewswire/ -- Biocept, Inc. ("Biocept"), an emerging leader in biotechnology, announced today the appointment of Bruce E. Gerhardt as Director.

"We are pleased to welcome Bruce to our Board. His experience will be invaluable to us as we move into our next stage of development," said Stephen M. Coutts, President and CEO.

Mr. Gerhardt has been a practicing Certified Public Accountant since 1986.  He is also a tax and business advisor providing tax compliance for small businesses and upper income individuals.  He earned his Bachelor of Arts Degree from the University of Southern California in 1973 and is a member of the American Institute of Certified Public

About Biocept

Biocept, an emerging biotechnology leader in cell separation technology, is developing novel diagnostic assays for personalized medicine in detection and monitoring of recurrent cancer. The CEE(TM) Cell Enrichment and Extraction platform combines sophisticated attachment chemistry with mathematically modeled fluid dynamics to enable earlier, accurate and less invasive diagnoses. Isolation, purification and genetic analysis of rare cells, such as circulating tumor cells, are managed within our state-of-the-art CLIA-accredited laboratory. The clinical laboratory is accredited by the College of American Pathologists (CAP) and holds licenses in California and several other states.


SOURCE Biocept, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Biocept, Inc. Announces Two New Director Appointments
2. Biocept, Inc. Announces CEO and Director Appointments
3. GeneWize Announces New Skin Clearing Product and Teen Nutrition at Annual Convention
4. Spherix Announces Statistically Significant Results in Phase 3 Study With D-tagatose in Type 2 Diabetes
5. GeneGo Announces Integration With GenomeQuest for Pathway Analysis of Next Generation Sequencing Data
6. Angiotech Pharmaceuticals, Inc. Announces Commencement of Arbitration and Litigation Proceedings by QSR Holdings, Inc. Against the Company And Certain of Its Subsidiaries
7. Aeterna Zentaris Announces Orphan Drug AEZS-130 (Macimorelin, Solorel(TM)) Interim Phase 3 Data Analysis Shows Potential for 2011 Filing as Oral Diagnostic Test for Adult Growth Hormone Deficiency (AGHD)
8. Jazz Pharmaceuticals Announces Paragraph IV ANDA Filing for Xyrem
9. Ground Zero Pharmaceuticals Announces Expansion of Global Consulting in Somatic Cell Therapies
10. MiMedx Group, Inc. Announces Release Date For Third Quarter Results
11. Shionogi Announces FDA Approval of KAPVAYâ„¢ - The First and Only Therapy Approved for Use with Stimulant Medication for the Treatment of ADHD
Post Your Comments:
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Ky. , June 23, 2016 ... two Phase 1 clinical trials of its complement ... placebo-controlled, single and multiple ascending dose studies designed ... pharmacodynamics (PD) of subcutaneous injection in healthy adult ... subcutaneously (SC) either as a single dose (ranging ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance Associates® Inc. (RCA), ... free webinar on Performing Quality Investigations: Getting to Root Cause. ... no charge. , Incomplete investigations are still a major concern to the Regulatory ...
Breaking Biology Technology:
(Date:5/12/2016)... 12, 2016 , a brand ... overview results from the Q1 wave of its quarterly ... was consumers, receptivity to a program where they would ... health insurance company. "We were surprised to ... Michael LaColla , CEO of Troubadour Research, "primarily ...
(Date:4/28/2016)... India , April 28, 2016 ... Infosys (NYSE: INFY ), and Samsung SDS, a ... that will provide end customers with a more secure, ... services.      (Logo: ) , ... services, but it also plays a fundamental part in enabling ...
(Date:4/26/2016)... Research and Markets has announced ... 2016-2020"  report to their offering.  , ,     (Logo: ... analysts forecast the global multimodal biometrics market to ... period 2016-2020.  Multimodal biometrics is being ... the healthcare, BFSI, transportation, automotive, and government for ...
Breaking Biology News(10 mins):